Good day, welcome to the OnKure Therapeutics, Inc annual meeting of stockholders. I would now like to turn the conference over to Nick Saccomano. Please go ahead.
Good morning. The meeting is called to order. As indicated, I am Nick Saccomano, President, CEO, and a Director of OnKure Therapeutics. I will act as Chair of the meeting. Rogan Nunn, our Corporate Secretary and General Counsel, will act as Secretary of the meeting and take minutes of the meeting. At this time, I would like to introduce the other directors in attendance. I would also like to introduce the other corporate officers who are in attendance, Jason Leverone, our Chief Financial Officer, Sam Agresta, our Chief Medical Officer, and Dylan Hartley, our Chief Scientific Officer. Also with us today are Erica Secor and Mike Petry, representing KPMG LLP, and Paul R. Ramirez, representing Broadridge Financial Solutions. Now I will ask Mr. Nunn to make his report.
Thank you. I have received an affidavit of mailing stating that the notice of Internet availability of proxy materials was first sent or given on April 21st, 2026, to the stockholders of record as of the close of business on April 16th, 2026, the record date for the meeting. A copy of the affidavit will be filed with the minutes of the meeting. The Inspector of Election for this meeting has signed an oath to execute faithfully the duties of the Inspector of Elections at the meeting. A copy of the oath will also be filed with the minutes of the meeting. The Inspector of Election has advised me that we have present, virtually or by proxy, a sufficient number of shares to constitute a quorum on all matters being presented at the meeting.
Thank you. This meeting is duly constituted, and we may proceed with business.
As set forth in the notice of Internet availability of proxy materials and further described in the proxy statement, the business of this meeting is to, number one, elect three nominees to the company's board of directors as Class II directors. Number two, ratify KPMG LLP as the company's independent registered public accounting firm. Three, amend and restate the OnKure Therapeutics, Inc 2024 Equity Incentive Plan to, among other things, increase the number of shares of our Class A common stock reserved for issuance by approximately 8% of our outstanding shares and remove the annual limit of 2,407,100 shares, which is after giving effect to the one-for-10 reverse stock split from October 4th, 2024, from the evergreen provision.
The first item of business is the election of three Class II directors to hold office until our 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The nominees for election designated by our board of directors are R. Michael Carruthers, Valerie M. Jansen, MD, PhD, and Edward T. Mathers. Our board of directors recommends a vote for the election of each of these nominees. The second item of business is to ratify the appointment of KPMG as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. Our board of directors recommends a vote for the ratification of KPMG.
The third item of business is to amend and restate the OnKure Therapeutics, Inc 2024 Equity Incentive Plan to, among other things, increase the number of shares of our Class A common stock reserved for issuance by approximately 8% of our outstanding shares and remove the annual limit of 2,407,100 shares after giving effect to the 1-for-10 reverse stock split effected on October 4th, 2024, from the evergreen provision. Our board of directors recommends a vote for the amendment and restatement of the 2024 Equity Incentive Plan.
We will now proceed to the question and answer period. I remind you that the meeting has been called for the purpose of considering the items of business described above. Please confine your questions and comments to those matters. If anybody has questions or comments regarding the proposals previously described, please submit your question or comment by inputting your questions into the Q&A text box on your screen and clicking submit.
All right, looks like we have no questions.
I direct that the vote be taken among all those who have not already voted upon the matters before the meeting or those revoking their prior votes and voting. The polls are now open at 7:04 A.M. Mountain Daylight Time.
Please note that we will vote by proxy and by online ballot. Each holder of Class A common stock is entitled to one vote for each share held at the close of business on the record date. If you've turned in a proxy and do not intend to change your vote, then it's not necessary that you vote at this meeting because we will count your proxy. Those of you who did not turn in a proxy or wish to change your vote may do so by clicking the vote link on the website used to access this meeting and following the instructions. The votes cast today will be counted in the final tally along with the proxies previously received.
If you're eligible to vote and have not submitted your proxy, or if you want to change your vote, please do so now by voting or updating your vote at www.virtualshareholdermeeting.com/okur2026.
Now that everyone has had the opportunity to vote, I hereby declare that the polls closed at 7:06 A.M. Mountain Daylight Time with respect to each matter to be voted on at this meeting.
The inspector will now tabulate the proxies and votes. At this time, I'm pleased to report that based on the current tabulation of votes, Mr. Carruthers, Mr. Mathers, and Dr. Jansen have been elected as Class II directors. The appointment of KPMG to act as the company's independent registered public accounting firm for the fiscal year ended December 31st, 2026, has been ratified, and the amendment and restatement of the 2024 Equity Incentive Plan has been approved. These are the preliminary results of voting. The final count may vary according to final examination of the votes. I direct that the report of the Inspector of Election be filed with the minutes of the meeting. The final results will also be filed with the SEC on Form 8-K within four business days of today's meeting.
This concludes the meeting, and the meeting is now adjourned. Thank you.